11
Participants
Start Date
May 26, 2023
Primary Completion Date
May 31, 2029
Study Completion Date
May 31, 2029
Cemiplimab
Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.
Peter MacCallum Cancer Centre, Melbourne
Collaborators (1)
University of Melbourne
OTHER
University of Adelaide
OTHER
Monash University
OTHER
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY
Peter MacCallum Cancer Centre, Australia
OTHER